Select region:

Clinical trials located in

Rome

Rome city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Rome, Italy’s capital, is steeped in history and culture, spanning over 28 centuries. Known as the “Eternal City,” it was once the heart of the Roman Empire. Rome houses the Vatican City, an independent country within its boundaries, making it unique. The city is home to invaluable art and architecture, including the Colosseum, Pantheon, and St. Peter’s Basilica. Rome’s historical layers are visible in its urban fabric, blending ancient ruins, Renaissance artistry, and modern life. It also introduced the world to aqueducts, which were crucial for its growth and the development of cities everywhere.

  • CT-EU-00112545

    Evaluating the Safety and Effectiveness of DYNE-101 for Myotonic Dystrophy Type 1 Patients

    This clinical trial is focused on evaluating a new treatment called DYNE-101 for individuals with Myotonic Dystrophy Type 1 (DM1). The main goal is to see how safe and tolerable this treatment is when given through an intravenous (IV) infusion, which means directly into the vein. The study is designed to carefully monitor how participants respond to multiple doses of DYNE-101 over time.

    The trial is structured into four main phases. It starts with a Screening Period that lasts up to 8 weeks to determine eligibility. Following this, there is a multiple-ascending dose (MAD) Placebo-Controlled Period that goes on for 24 weeks, where the safety and effectiveness of different doses of DYNE-101 are compared against a placebo (a treatment with no active drug). This is to ensure that any changes in participants’ health can be accurately attributed to the treatment. After this phase, there is a Treatment Period of another 24 weeks, where all participants receive DYNE-101. The study concludes with a Long-Term Extension (LTE) Period lasting 96 weeks, aimed at understanding the long-term impacts of the treatment.

    One of the key aspects being monitored throughout the study, up to Week 145, is the number of participants who experience any treatment-emergent adverse events (TEAEs), which are any new or worsening health issues that occur during the trial.

    This study represents an important step towards finding a new treatment option for those living with Myotonic Dystrophy Type 1, with a strong focus on safety and the overall well-being of the participants.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • A study on lymph node dissection in adrenal cancer surgery

    This is a study aimed at understanding the role of lymph node dissection in the surgical treatment of adrenocortical carcinoma (ACC), a rare and aggressive form of cancer affecting the adrenal glands. The aim of this study is to collect information from the EUROCRINE® database, focusing on patients who have undergone adrenalectomy, or surgical removal of the adrenal gland, for ACC.

    The basis of the examination is to check how extensive the lymph nodes are removed during the operation. Lymph nodes play a key role in the body’s immune system and can be a way for cancer to spread. Therefore, it is important to understand the extent of lymph node dissection, including the number of lymph nodes and nodal stations resected. This will help assess the effectiveness of surgery in completely removing the cancer and its impact on the rate of cancer recurrence and nodal metastases, i.e. the spread of the cancer to the lymph nodes.

    The research focuses particularly on analyzing the results depending on the stage of the disease and the location of the tumor in the left or right adrenal gland. Given the complexity of adrenal lymphatic drainage and the high risk of recurrence even after successful surgery, this study aims to shed light on the optimal surgical approach to improve patient outcomes.

    Italy
  • A study of relacorilant in the treatment of hypercortisolism (Cushing’s syndrome) in patients with adrenal adenoma

    This clinical trial focuses on testing the effectiveness and safety of a drug called relacorilant in the treatment of patients with hypercortisolism (Cushing’s syndrome). Hypercortisolism is a condition in which there is too much cortisol in the body, which may occur due to an adenoma or hyperplasia of the adrenal glands that secrete cortisol. This condition can lead to diabetes or impaired glucose tolerance and/or uncontrolled high blood pressure.

    The study is in phase III, which means that the effectiveness and safety of the drug are compared with placebo. This is a double-blind, placebo-controlled study, which means neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo to ensure unbiased results.

    Participants in this study will be randomly assigned to receive relacorilant or placebo for 22 weeks. The main goals of the study are to see how well relakorilant can improve blood sugar levels in patients with diabetes or impaired glucose tolerance, and how it affects blood pressure in people with high blood pressure. Additionally, the study will monitor the safety of relacorilant by recording any adverse events that occur.

    People who complete the study may have the opportunity to continue with a follow-up study, which may provide further information on the long-term effects and benefits of relacorilant.

    AustriaBulgariaGermanyItalyPolandRomaniaSpain
  • Clinical Study on Growth and Health in Children with Achondroplasia

    This is a long-term, multi-center, observational study for children aged 2.5 to <17 years who have been diagnosed with achondroplasia. The main objective of the study is to evaluate various aspects of the condition, including growth, medical complications related to achondroplasia, health-related quality of life, body pain, functional abilities, cognitive functions, and treatments received by the participants. The study will monitor changes in height Z score and upper to lower body segment ratio over a period of up to 2 years. No study medication will be administered to the participants during this observational study.

    FranceGermanyItalyNorwaySpainUnited Kingdom
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    AustriaBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Assessing imatinib inhalation therapy for pulmonary arterial hypertension

    This clinical study aims to evaluate the safety and efficacy of an inhaled treatment called imatinib (AV-101) for patients with Pulmonary Arterial Hypertension (PAH). The trial is divided into two parts: Phase 2b and Phase 3. In Phase 2b, researchers will test three doses of AV-101 to identify the optimal dose for Phase 3. They will check this by measuring the resistance of the lung vessels — less resistance means the medicine is working. In the following Phase 3, the primary outcome will be the change in the 6-minute walk distance after 24 weeks of treatment compared to a placebo. Participants must be between 18 and 75 years old, have a diagnosis of PAH, and meet specific criteria regarding their disease severity and concomitant therapy.

    AustriaBelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Trial for high-risk Lymphoma Patients comparing Axicabtagene Ciloleucel and standard therapy

    In this study, the researchers are trying to find out if a new drug called Axicabtagene Ciloleucel is a better first treatment for a type of blood cancer known as high-risk large B-cell lymphoma, compared to the current standard treatment. This is a big study, done in many places, where patients will be randomly picked to get either the new drug or the current standard treatment. Five years after the last patient joins the study, those who had the new drug will join another study to see how they are doing for the next 10 years. The study will look at a few things, like how long until the disease gets worse, how many people’s cancer has gone away after the treatment, and how their quality of life and health status are, using different questionnaires.

    AustriaFranceItalyNetherlandsPortugalSpainUnited Kingdom
  • Examining repotrectinib vs crizotinib in advanced lung cancer treatment

    This trial is named TRIDENT-3, it’s for people who have a particular type of lung cancer that has spread beyond the lungs (advanced or metastatic). The lung cancer for this study is called ‘Non-Small Cell Lung Cancer’ (NSCLC) and it’s positive for an important part of the cells called ‘ROS1.’ The trial will compare two medicines: repotrectinib and crizotinib. People participating in the trial have not been treated with a group of drugs called ‘Tyrosine Kinase Inhibitors’ (TKIs) before. The main goal of this study is to see how effective and safe these two drugs are for these patients.

    AustriaFranceGermanyGreeceHungaryItalyPolandRomaniaSpain
  • Testing selinexor for relapsed large B-Cell lymphoma

    This clinical trial is about testing a drug called Selinexor on patients who have a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (DLBCL) that has returned or hasn’t responded to treatment. Lymphoma is a type of cancer that starts in cells that are part of the body’s immune system. The trial is divided into two parts. In Part 1, the researchers will give 130 patients a 60mg dose of this drug to see how they respond. These patients have no other treatment options. In Part 2, the researchers will divide about 110 patients into two groups. One group will receive a 40mg dose and the other a 60mg dose. All the patients will be closely monitored until their disease progresses. The results of the study will be based on international guidelines and standards for assessing lymphoma.

    GreeceItalyPoland
  • Testing the safety and effectiveness of a new drug on patients with Duchenne muscular dystrophy

    This study aims to test DYNE-251, a new medicine for people with a specific type of Duchenne muscular dystrophy (amenable to exon 51 skipping)- a muscle weakening disease. The goal is to evaluate if it’s safe, if people can tolerate it well, and if it helps produce a crucial muscle protein called dystrophin. Participants will be given DYNE-251 intravenous in the increasing doses in several stages. The study includes different phases, starting with a 24-week test period, followed by long-term observation. To measure the effects, the researchers will use a functional scale for motor abilities and a score for upper limb function.

    BelgiumItalySpainUnited Kingdom
  • Fianlimab and cemiplimab: a new treatment for melanoma patients

    The study is underway to determine the most effective treatments in preventing the recurrence of melanoma, a form of skin cancer, following surgical removal. The medicines being tested are Fianlimab and Cemiplimab together or another medicine called Pembrolizumab. The trial aims to assess whether the Fianlimab and Cemiplimab combination outperforms Pembrolizumab in preventing cancer recurrence and if patients administered Fianlimab and Cemiplimab live longer. Additionally, the study seeks insights into the impact of treatments on patients’ quality of life, the occurrence of minor or major side effects, and how these drugs behave inside the patient’s body.

    BelgiumCzechiaFranceGermanyGreeceItalyPolandRomaniaSpainUnited Kingdom
  • Study relating to new treatment for ovarian cancer

    This is a study for patients who have ovarian, fallopian tube, or primary peritoneal cancer that has resisted platinum-based treatments. The main goal is to see how well two drugs, Nemvaleukin Alfa and Pembrolizumab, work together compared to other chemotherapy treatments that the doctor chooses. Patients will be picked randomly by a computer to receive either the two-drug combo, one of the two drugs alone, or other chemo drugs, such as doxorubicin, paclitaxel, topotecan, or gemcitabine. This study is open, which means everyone will know which treatment is being given.

    AustriaBelgiumCzechiaFranceGermanyItalySpainUnited Kingdom
  • Testing inhaled imatinib for pulmonary arterial hypertension

    This study is about a new medicine called imatinib (AV-101) which you breathe in as a dry powder. It’s for people who have a health problem called Pulmonary Arterial Hypertension (PAH) – when blood pressure is too high in the arteries that go from the heart to the lungs. The imatinib study will go through two stages. In the first stage, the researchers will try three different amounts of the medicine to find the best one. It will be based on how much it can reduce the resistance in the blood flow in the lungs. In the second stage, they it will be seen how far patients can walk in 6 minutes after taking the medicine for 24 weeks. The study also uses scoring systems to measure how much risk or symptoms a patient has. A higher score means more risk or symptoms.

    AustriaBelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Testing safety and effects of telisotuzumab and docetaxel in Lung Cancer patients

    This study is for adults who have been treated before for a type of lung cancer called non-small cell lung cancer (NSCLC). The aim is to see if a new drug, called telisotuzumab vedotin, works better and is as safe as a common drug called docetaxel. In this study, cancer activity and any side-effects will be observed closely. The treatment will be given by a drip into a vein.The researchers will randomly decide whether each participant will get telisotuzumab vedotin or docetaxel, with an equal chance of getting either drug. While in the study, each person will have regular hospital or clinic visits to check how they are doing with tests and questionnaires.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    AustriaDenmarkFranceGermanyItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing zimberelimab and domvanalimab with chemotheraphy for lung cancer

    This clinical trial explores the effectiveness of two new medicines, zimberelimab and domvanalimab, in tandem with chemotherapy for patients with untreated metastatic non-small cell lung cancer. The study’s main goal is to compare the impact and success of this combination treatment versus a control group receiving pembrolizumab along with chemotherapy. The hopeful outcome of the trial is to identify whether the new combination of drugs can provide enhanced benefits for the involved patients. Regular health monitoring will occur during the trial to ensure patient safety.

    AustriaBelgiumFranceGermanyItalyNetherlandsPortugalSpainUnited Kingdom
  • Comparison of drug combinations in the treatment of advanced lung cancer

    This trial studies a first-line treatment involving Dato-DXd plus pembrolizumab compared to pembrolizumab alone in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The goal is to evaluate the effectiveness and safety of this combined strategy. Target volunteers must not have received any treatments for their advanced or metastatic NSCLC. Participation includes receiving either the combined treatment or pembrolizumab alone. Regular health checks will monitor if any changes or adverse events occur during the trial.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Examining new drug combo vs. standard treatment with pembrolizumab for advanced lung cancer

    This trial is examining if a combination of two medications, Dato-DXd and pembrolizumab, could be superior to using pembrolizumab alone in treating a type of lung cancer known as metastatic non-small cell lung cancer (NSCLC). Participants will include those who have advanced or spread NSCLC and haven’t had systemic treatment for it. The team will be comparing whether the combination treatment can help patients live longer or keep the cancer from growing for a longer period. One group of participants will get pembrolizumab on its own, while another will get both Dato-DXd and pembrolizumab. An important part of the study will assess how the treatment affects the patient’s symptoms and quality of life.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom

See more clinical trials in other cities in Italy:

.